10-Q · May 13, 2026
HeartBeam reported a Q1 2026 net loss of $4.7 million, which reflects a 14% improvement from a loss of $5.5 million in Q1 2025. Operating expenses decreased by 14% to $4.716 million, driven by a reduction in R&D costs,…
Earnings analysis · 10-Q
BEAT earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
The provided 10-Q extract does not include the income statement, balance sheet, cash-flow statement, MD&A, or segment disclosures, so revenue, margins, EPS, cash flow, liquidity, and year-over-year trends cannot be…
Read full summary
The provided 10-Q extract does not include the income statement, balance sheet, cash-flow statement, MD&A, or segment disclosures, so revenue, margins, EPS, cash flow, liquidity, and year-over-year trends cannot be assessed. The filing does report effective disclosure controls as of June 30, 2026, no material control changes during the quarter, no material legal proceedings, and no derivatives or hedging activities. No quantitative guidance or risk-factor updates were provided.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Disclosure controls deemed effective
Management concluded that disclosure controls and procedures were effective as of June 30, 2026, providing reasonable assurance that required information is reported within SEC timelines.
-
No material control changes
The company reported no changes in internal control over financial reporting during the fiscal quarter ended June 30, 2026 that materially affected, or were reasonably likely to materially affect, those controls.
-
No derivatives or hedging exposure
The company stated that it does not hold derivative instruments and does not engage in hedging activities; quantitative and qualitative market-risk disclosures were not required because it is a smaller reporting company.
-
No material legal proceedings
Management stated that no legal actions, suits, proceedings, inquiries, or investigations were pending or threatened in which an adverse decision could have a material adverse effect.
What to watch
-
No updated risk-factor disclosure
Risk Factor disclosure was marked “Not applicable” under Item 1A because HeartBeam qualifies as a smaller reporting company. Accordingly, the filing provides no updated risk-factor detail versus the prior report.
-
No hedging protection
The company stated it does not hold derivative instruments or engage in hedging activities under Item 3; therefore, it has no reported hedge protection against market-risk exposures.
Management's outlook
The provided 10-Q text contains no quantitative revenue or EPS outlook. Outlook and guidance were not provided in the filing.
Earlier filings 4
10-Q · November 13, 2025
HeartBeam reported a Q3 net loss of $5.255 million (EPS $(0.15)), slightly wider sequentially vs Q2 but improved versus prior-year quarter EPS ($(0.19)). Operating expenses rose to $5.29 million driven by higher R&D;…
10-Q · August 14, 2024
HeartBeam reported a wider Q2 net loss of $4,956,000 (EPS -$0.19) versus $3,154,000 (EPS -$0.16) in Q2 2023, driven by higher operating expenses (Q2 operating expense $5,090,000 vs $3,312,000). Cash declined to…
10-Q · May 9, 2024
HeartBeam reported a net loss of $4,606,000 for the three months ended March 31, 2024, versus a $4,136,000 loss a year earlier; diluted loss per share improved to $(0.17) from $(0.50) due to a higher weighted average…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.